Abstract Number: 0757 • ACR Convergence 2022
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…Abstract Number: 1886 • ACR Convergence 2022
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…Abstract Number: 0771 • ACR Convergence 2022
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…Abstract Number: 2147 • ACR Convergence 2022
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…Abstract Number: 0777 • ACR Convergence 2022
Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
Background/Purpose: The advent of immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer. Patients with pre-existing autoimmune diseases (AID) were largely excluded from…Abstract Number: 0816 • ACR Convergence 2022
Increased Risk of Hepatotoxicity with DMARDS in Patients with Previous Liver Toxicity with Isoniazid: Study in a Single University Hospital
Background/Purpose: Isoniazid (INH) is used to treat latent tuberculosis infection (LTBI), and hepatotoxicity is one of the most frequent adverse effect. Several Disease-modifying drugs (DMARDs)…Abstract Number: 0929 • ACR Convergence 2022
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…Abstract Number: 0980 • ACR Convergence 2022
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…Abstract Number: 1076 • ACR Convergence 2022
ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…Abstract Number: 1081 • ACR Convergence 2022
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…Abstract Number: 0439 • ACR Convergence 2021
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…Abstract Number: 0646 • ACR Convergence 2021
Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of rheumatic diseases. The use of HCQ is complicated by HCQ-induced retinopathy, which may lead to…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 10
- Next Page »